miR‑4732‑5p promotes ovarian cancer mobility by targeting MCUR1

Li,Xin; Wang,Xiaoqin; Wu,Jun

doi:10.3892/ol.2023.13831

miR‑4732‑5p promotes ovarian cancer mobility by targeting MCUR1

Authors:
- Xin Li
- Xiaoqin Wang
- Jun Wu
View Affiliations

Affiliations: Department of Gynecology No. 5, Ningbo Women and Children's Hospital, Ningbo, Zhejiang 315012, P.R. China
Published online on: April 20, 2023 https://doi.org/10.3892/ol.2023.13831
Article Number: 245
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs/miRs) play critical roles in tumor progression. However, the role of miR‑4732 and its underlying molecular mechanism in ovarian cancer (OC) remain unclear. In the present study, the high expression of miR‑4732 was confirmed to be associated with the mortality of patients with OC following surgery, according to The Cancer Genome Atlas Ovarian Cancer database (TCGA‑OV). Additionally, the expression of miR‑4732 was positively associated with an increased tendency to exhibit an early TNM stage (IIA, IIB and IIC) of OC, indicating its promotional role in the early stages of tumorigenesis. By performing in vitro gain‑of‑function experiments, the transient transfection of IGROV1 cells with miR‑4732‑5p mimics enhanced cell viability according to Cell Counting Kit‑8 assay, and cell migration and invasion in Transwell assays. However, though the application of loss‑of‑function experiments, the transient transfection of IGROV1 cells with miR‑4732‑5p inhibitors hindered cell viability, cell migration and invasion in vitro. Mitochondrial calcium uniporter regulator 1 (MCUR1) was validated as a downstream direct target of miR‑4732‑5p through bioinformatics analysis, western blotting and luciferase assays. Therefore, the results of the present study provide evidence that miR‑4732‑5p may promote OC cell mobility through the direct targeting of the tumor suppressor, MCUR1.

View Figures

View References

1	Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer Statistics, 2021. CA Cancer J Clin. 71:7–33. 2021. View Article : Google Scholar : PubMed/NCBI
2	Rojas V, Hirshfield KM, Ganesan S and Rodriguez-Rodriguez L: Molecular characterization of epithelial ovarian cancer: Implications for diagnosis and treatment. Int J Mol Sci. 17:21132016. View Article : Google Scholar : PubMed/NCBI
3	Giampaolino P, Della Corte L, Foreste V, Vitale SG, Chiofalo B, Cianci S, Zullo F and Bifulco G: Unraveling a difficult diagnosis: The tricks for early recognition of ovarian cancer. Minerva Med. 110:279–291. 2019. View Article : Google Scholar : PubMed/NCBI
4	Stewart C, Ralyea C and Lockwood S: Ovarian cancer: An integrated review. Semin Oncol Nurs. 35:151–156. 2019. View Article : Google Scholar : PubMed/NCBI
5	Rupaimoole R and Slack FJ: MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
6	Bader AG: miR-34-a microRNA replacement therapy is headed to the clinic. Front Genet. 3:1202012. View Article : Google Scholar : PubMed/NCBI
7	Ottosen S, Parsley TB, Yang L, Zeh K, van Doorn LJ, van der Veer E, Raney AK, Hodges MR and Patick AK: In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122. Antimicrob Agents Chemother. 59:599–608. 2015. View Article : Google Scholar : PubMed/NCBI
8	Chen SN, Chang R, Lin LT, Chern CU, Tsai HW, Wen ZH, Li YH, Li CJ and Tsui KH: MicroRNA in Ovarian cancer: Biology, pathogenesis, and therapeutic opportunities. Int J Environ Res Public Health. 16:15102019. View Article : Google Scholar : PubMed/NCBI
9	Zheng H, Liu JY, Song FJ and Chen KX: Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer. Cancer Biol Med. 10:123–130. 2013.PubMed/NCBI
10	Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM and Cohn DE: The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol. 112:55–59. 2009. View Article : Google Scholar : PubMed/NCBI
11	Llaurado M, Majem B, Altadill T, Lanau L, Castellví J, Sánchez-Iglesias JL, Cabrera S, De la Torre J, Díaz-Feijoo B, Pérez-Benavente A, et al: MicroRNAs as prognostic markers in ovarian cancer. Mol Cell Endocrinol. 390:73–84. 2014. View Article : Google Scholar : PubMed/NCBI
12	Liu J, Yoo J, Ho JY, Jung Y, Lee S, Hur SY and Choi YJ: Plasma-derived exosomal miR-4732-5p is a promising noninvasive diagnostic biomarker for epithelial ovarian cancer. J Ovarian Res. 14:592021. View Article : Google Scholar : PubMed/NCBI
13	Li G, Ao S, Hou J and Lyu G: Low expression of miR-125a-5p is associated with poor prognosis in patients with gastric cancer. Oncol Lett. 18:1483–1490. 2019.PubMed/NCBI
14	Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29:e452001. View Article : Google Scholar : PubMed/NCBI
15	Tang Z, Li C, Kang B, Gao G, Li C and Zhang Z: GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45((W1)): W98–W102. 2017. View Article : Google Scholar : PubMed/NCBI
16	Bignone PA, Lee KY, Liu Y, Emilion G, Finch J, Soosay AE, Charnock FM, Beck S, Dunham I, Mungall AJ and Ganesan TS: RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer. Oncogene. 26:683–700. 2007. View Article : Google Scholar : PubMed/NCBI
17	Fan L, Yang H, Zhang B and Ding H: MCUR1 is a prognostic biomarker for ovarian cancer patients. Cancer Biomark. 33:311–316. 2022. View Article : Google Scholar : PubMed/NCBI
18	Chang X and Dong Y: CACNA1C is a prognostic predictor for patients with ovarian cancer. J Ovarian Res. 14:882021. View Article : Google Scholar : PubMed/NCBI
19	Wang K, Guan C, Shang X, Ying X, Mei S, Zhu H, Xia L and Chai Z: A bioinformatic analysis: The overexpression and clinical significance of FCGBP in ovarian cancer. Aging (Albany NY). 13:7416–7429. 2021. View Article : Google Scholar : PubMed/NCBI
20	Chen L, Hou J, You B, Song F, Tu X and Cheng X: An analysis regarding the prognostic significance of mavs and its underlying biological mechanism in ovarian cancer. Front Cell Dev Biol. 9:7280612021. View Article : Google Scholar : PubMed/NCBI
21	Zhang M and Zhao L: CKAP2 promotes ovarian cancer proliferation and tumorigenesis through the FAK-ERK pathway. DNA Cell Biol. 36:983–990. 2017. View Article : Google Scholar : PubMed/NCBI
22	Zhang RR, Wang LM and Shen JJ: Overexpression of miR-32 inhibits the proliferation and metastasis of ovarian cancer cells by targeting BTLA. Eur Rev Med Pharmacol Sci. 24:4671–4678. 2020.PubMed/NCBI
23	Zhai DK, Liu B, Bai XF and Wen JA: Identification of biomarkers and pathway-related modules involved in ovarian cancer based on topological centralities. J BUON. 21:208–220. 2016.PubMed/NCBI
24	Wang YW, Zhao S, Yuan XY, Liu Y, Zhang K, Wang J, Zhu J and Ma R: miR-4732-5p promotes breast cancer progression by targeting TSPAN13. J Cell Mol Med. 23:2549–2557. 2019. View Article : Google Scholar : PubMed/NCBI
25	Omura T, Shimada Y, Nagata T, Okumura T, Fukuoka J, Yamagishi F, Tajika S, Nakajima S, Kawabe A and Tsukada K: Relapse-associated microRNA in gastric cancer patients after S-1 adjuvant chemotherapy. Oncol Rep. 31:613–618. 2014. View Article : Google Scholar : PubMed/NCBI
26	Tang X, Liu S, Cui Y and Zhao Y: MicroRNA-4732 is downregulated in non-small cell lung cancer and inhibits tumor cell proliferation, migration, and invasion. Respir Med Res. 80:1008652021.PubMed/NCBI
27	Hu Y, Bai J, Zhou D, Zhang L, Chen X, Chen L, Liu Y, Zhang B, Li H and Yin C: The miR-4732-5p/XPR1 axis suppresses the invasion, metastasis, and epithelial-mesenchymal transition of lung adenocarcinoma via the PI3K/Akt/GSK3β/Snail pathway. Mol Omics. 18:417–429. 2022. View Article : Google Scholar : PubMed/NCBI
28	Kim J, Yu L, Chen W, Xu Y, Wu M, Todorova D, Tang Q, Feng B, Jiang L, He J, et al: Wild-Type p53 promotes cancer metabolic switch by inducing PUMA-Dependent suppression of oxidative phosphorylation. Cancer Cell. 35:191–203. e82019. View Article : Google Scholar : PubMed/NCBI
29	Alevriadou BR, Patel A, Noble M, Ghosh S, Gohil VM, Stathopulos PB and Madesh M: Molecular nature and physiological role of the mitochondrial calcium uniporter channel. Am J Physiol Cell Physiol. 320:C465–C482. 2021. View Article : Google Scholar : PubMed/NCBI